Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01343316 · ClinicalTrials.gov registry record

Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients

A clinical trial, sponsored by Johns Hopkins University.

Terminated
Registry status
21
Enrollment target

NCT01343316: Clinical Trial study, sponsored by Johns Hopkins University.

NCT01343316 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01343316 was terminated before completion, sponsored by Johns Hopkins University.

TERMINATED
Registry status
21 participants
Enrollment target

Study Summary

The purpose of this study is to determine the benefit of feeding critically-ill patients beyond the stomach (post-pyloric). Furthermore, because of the advent of two new post-pyloric feeding tubes (Tiger 2 and Syncro BlueTube) designed to improve post-pyloric placement, the investigators will be evaluating the benefits of those two tubes as well.

Primary Outcome

To determine the time to goal calories. To determine the number and qualitative aspect of tracheal aspirations. To determine the time to initiate tube feeds once the decision has been made to place a tube, the number of x-rays required for placement, the time required for placement, the number of times tube needs to be replaced.

Interventions

  • DEVICE Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2010-11
Est. Completion 2013-03
Johns Hopkins University

1,448 total trials

Why NCT01343316 stopped before completion

NCT01343316 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube) is the first listed.

NCT01343316 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01343316 about?

NCT01343316 is a clinical study titled "Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients". The purpose of this study is to determine the benefit of feeding critically-ill patients beyond the stomach (post-pyloric). Furthermore, because of the advent of two new post-pyloric feeding tubes (Tiger 2 and Syncro BlueTube) designed to improve post-pyloric placement, the investigators will be eva...

What is the current status of trial NCT01343316?

This trial is currently terminated. The enrollment target is 21 participants. The study started on 2010-11. Estimated completion is 2013-03.

What interventions are being tested in trial NCT01343316?

The interventions under investigation include: Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube) (DEVICE).

Who is sponsoring clinical trial NCT01343316?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01343316, the US trial registry maintained by the National Library of Medicine. NCT01343316 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.